Aeolus Pharmaceuticals Inc. (AOLS.OB)

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops various therapeutic agents based on its proprietary small molecule catalytic antioxidant compounds for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. It primarily focuses on the development of AEOL 10150, which is in Phase Ib multiple dose study product, a small molecule catalytic antioxidant to scavenge a range of reactive oxygen species, or free radicals. The AEOL 10150 mimics and amplifies the body’s natural enzymatic systems for eliminating these damaging compounds. Its products under development also include AEOL 11207, AEOL 11203, and AEOL 11216, which are in pre-clinical trials. The company was founded in 1994 and is based in Laguna Niguel, California.